Kezar Life Sciences Inc.(KZR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KZR Kezar Life Sciences Inc.

Halted 05-20 18:11:40 EDT

7.29

+0.00

0.00%

High7.29	Low7.29	Vol0.00
Open7.29	D1 Closing7.29	Amplitude0.00%
Mkt Cap53.74M	Tradable Cap34.20M	Total Shares7.37M
T/O0.00	T/O Rate0.00%	Tradable Shares4.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KZR","market":"US","secType":"STK","nameCN":"Kezar Life Sciences Inc.","latestPrice":7.29,"timestamp":1779307200000,"preClose":7.29,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":4691522,"shares":7371527,"eps":-7.66,"marketStatus":"Halted","change":0,"latestTime":"05-20 18:11:40 EDT","open":7.29,"high":7.29,"low":7.29,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.66,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779321600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":7.29,"volumeRatio":0},"requestUrl":"/m/hq/s/KZR","defaultTab":"news","newsList":[{"id":"2636485673","title":"Aurinia completes tender offer for Kezar, wins 80% of shares tendered","url":"https://stock-news.laohu8.com/highlight/detail?id=2636485673","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636485673?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:33","pubTimestamp":1779193990,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals completed its tender offer for Kezar Life Sciences, with 5,927,580 shares tendered, representing 80.24% of Kezar’s outstanding shares.The tendered shares had an aggregate value of about $41.23 million.The offer price was $6.96 in cash per share, with one non-transferable contingent value right issued for each share tendered.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL63J81g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139","KZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634323264","title":"Kezar Life Sciences’ Risk Disclosures Rely on Cross-References, Potentially Obscuring Full Risk Picture for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2634323264","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634323264?lang=en_us&edition=fundamental","pubTime":"2026-05-12 14:01","pubTimestamp":1778565695,"startTime":"0","endTime":"0","summary":"Kezar Life Sciences (KZR) has disclosed a new risk, in the Regulation category. The disclosure directs investors to Part I of Kezar Life Sciences’ ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kezar-life-sciences-risk-disclosures-rely-on-cross-references-potentially-obscuring-full-risk-picture-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kezar-life-sciences-risk-disclosures-rely-on-cross-references-potentially-obscuring-full-risk-picture-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KZR","BK4211","BK4139","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634284076","title":"Aurinia completes Kezar acquisition at $6.96 per share plus CVR","url":"https://stock-news.laohu8.com/highlight/detail?id=2634284076","media":"Reuters","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634284076?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:21","pubTimestamp":1778505698,"startTime":"0","endTime":"0","summary":"Aurinia completed acquisition of Kezar Life Sciences via tender offer priced at USD 6.96 per share in cash plus one contingent value right.Offer expired May 8, 2026 with 5,927,580 shares tendered, representing about 80.24% of outstanding shares.Merger closed May 11, 2026, leaving Kezar as a wholly owned subsidiary of Aurinia’s US unit.Outstanding Kezar options vested at closing, with in-the-money awards converted into cash based on spread to cash price plus CVRs; out-of-the-money options were cancelled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8X8FY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZR","BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634407620","title":"Kezar Q1 net loss narrows to $5.8 million; operating loss narrows to $7.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634407620","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634407620?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:08","pubTimestamp":1778494118,"startTime":"0","endTime":"0","summary":"Kezar Life Sciences posted a net loss of USD 5.8 million for the quarter ended March 31, 2026, narrowing from USD 16.6 million a year earlier.Operating loss narrowed to USD 7.4 million from USD 17.7 million, with total operating expenses dropping to USD 7.4 million from USD 17.7 million.Research and development expense fell to USD 1.5 million from USD 12.2 million, while general and administrative expense edged down to USD 5.2 million from USD 5.5 million.Interest income slipped to USD 0.6 million from USD 1.4 million, while the quarter included a USD 1 million gain on sale of a nonfinancial asset.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kezar Life Sciences Inc. published the original content used to generate this news brief via","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL3B2hdJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH","KZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633345166","title":"Kezar Life Sciences Inc  expected to post a loss of 86 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633345166","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633345166?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:04","pubTimestamp":1778245447,"startTime":"0","endTime":"0","summary":"Kezar Life Sciences Inc  expected to post a loss of86cents a share - Earnings Preview Kezar Life Sciences Inc KZR.OQ KZR.O is expected to  show no change in quarterly revenue when it reports  results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1FM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631573255","title":"Kalamazoo Taps BurnVoir to Drive Financing for Ashburton Gold Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2631573255","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631573255?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:38","pubTimestamp":1777505883,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Kalamazoo Resources Ltd. ( ($AU:KZR) ). Kalamazoo Resources has appointed specialist corporate finance firm Bur...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kalamazoo-taps-burnvoir-to-drive-financing-for-ashburton-gold-project?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kalamazoo-taps-burnvoir-to-drive-financing-for-ashburton-gold-project?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KZR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629706690","title":"Kalamazoo advances Ashburton drilling, raises A$12.1m and names new CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2629706690","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629706690?lang=en_us&edition=fundamental","pubTime":"2026-04-21 10:48","pubTimestamp":1776739684,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Kalamazoo Resources Ltd. ( ($AU:KZR) ). Kalamazoo Resources has reported a strong March quarter, highlighting p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kalamazoo-advances-ashburton-drilling-raises-a12-1m-and-names-new-ceo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kalamazoo-advances-ashburton-drilling-raises-a12-1m-and-names-new-ceo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629706618","title":"Kalamazoo Resources Boosts Cash Reserves Through Equity Funding Amid Exploration Spend","url":"https://stock-news.laohu8.com/highlight/detail?id=2629706618","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629706618?lang=en_us&edition=fundamental","pubTime":"2026-04-21 10:27","pubTimestamp":1776738479,"startTime":"0","endTime":"0","summary":"Kalamazoo Resources Ltd. ( ($AU:KZR) ) has issued an announcement. Kalamazoo Resources Ltd. reported its quarterly cash flow for the period ended 3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-boosts-cash-reserves-through-equity-funding-amid-exploration-spend?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-boosts-cash-reserves-through-equity-funding-amid-exploration-spend?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQR","BK4139","BK4585","BK4215","BK4588","KZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625919790","title":"Kalamazoo Director Increases Equity Stake with On-Market Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2625919790","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625919790?lang=en_us&edition=fundamental","pubTime":"2026-04-08 16:29","pubTimestamp":1775636962,"startTime":"0","endTime":"0","summary":"Kalamazoo Resources Ltd. ( ($AU:KZR) ) has shared an update. Kalamazoo Resources Ltd. has reported a change in director Benjamin Ackerman’s holding...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kalamazoo-director-increases-equity-stake-with-on-market-share-purchase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kalamazoo-director-increases-equity-stake-with-on-market-share-purchase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4215","EQR","BK4588","KZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624625662","title":"Kezar Life Sciences Announces Major Executive Leadership Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2624625662","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624625662?lang=en_us&edition=fundamental","pubTime":"2026-04-04 05:27","pubTimestamp":1775251641,"startTime":"0","endTime":"0","summary":"Kezar Life Sciences ( ($KZR) ) has issued an announcement. On April 1, 2026, Kezar Life Sciences terminated its lease for 48,714 square feet of off...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kezar-life-sciences-announces-major-executive-leadership-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kezar-life-sciences-announces-major-executive-leadership-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KZR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664225","title":"Aurinia Pharma to buy Kezar Life Sciences for $6.955 a share plus CVR","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664225","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664225?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:58","pubTimestamp":1775249915,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals agreed to acquire Kezar Life Sciences for USD 6.955 per share in cash plus a non-transferable contingent value right.CVR provides potential payouts tied to development or disposition of Kezar lead asset zetomipzomib, selected collaboration and asset-sale proceeds, and net cash above USD 50 million at closing.Aurinia plans to launch a tender offer by April 13, 2026, for all outstanding Kezar shares.Closing is expected in Q2 2026, subject to a majority of shares tendered and Kezar meeting a net-cash condition above USD 50 million.Tang Capital Partners, holding about 9.0% of Kezar shares, signed a tender and support agreement backing transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceutical","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL9hGLjS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZR","AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664400","title":"Kezar Life Sciences CEO Kirk, CFO Belsky, COO Schiller exit under separation agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664400","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664400?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:50","pubTimestamp":1775249410,"startTime":"0","endTime":"0","summary":"Kezar Life Sciences entered separation agreements on April 1, 2026 with Chief Executive Officer Christopher J. Kirk, Chief Financial Officer Marc L. Belsky, and Chief Operating Officer Mark Schiller.Employment for all three executives will terminate at effective time specified in the agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kezar Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDLc2qBx4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623321125","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Aura Biosciences Inc (AURA) and Kezar Life Sciences (KZR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623321125","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623321125?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:50","pubTimestamp":1774903807,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aura Biosciences Inc (AURA) and Kezar Life Science...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-aura-biosciences-inc-aura-and-kezar-life-sciences-kzr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-aura-biosciences-inc-aura-and-kezar-life-sciences-kzr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU0029874061.USD","LABU","BK4139","BK4588","XBI","KZR","BK4581","LU0128526141.USD","XLV","AURA","HCSG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623326235","title":"Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2623326235","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623326235?lang=en_us&edition=fundamental","pubTime":"2026-03-31 03:56","pubTimestamp":1774900569,"startTime":"0","endTime":"0","summary":"After Aurinia Pharmaceuticals (AUPH) announced an agreement to acquire Kezar Life Sciences (KZR) for $6.955 in cash per share plus one non-transfer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kezar-life-sciences-takeover-valuation-makes-sense-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kezar-life-sciences-takeover-valuation-makes-sense-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KZR","AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623342665","title":"BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar","url":"https://stock-news.laohu8.com/highlight/detail?id=2623342665","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623342665?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:53","pubTimestamp":1774886000,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, KezarWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL6N40I13J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSX","CDE","ADMA","BX","KALU","CENX","RARE","XOMX","BIIB","ADNT","MMYT","SYY","IDYA","DVN","CRWD","GPI","NVAX","VRDN","GM","APO","SSII","AA","BFLY","CNTB","UTHR","XOMO","ALV","CL","NEMG","ZYME","HL","CG","SR","INSM","CART","KKR","FLEX","ALK","KZR","GEVO","PUMP","NEM","EXPE","PWR","SOC"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2623349259","title":"Kezar Life Sciences to Be Acquired by Aurinia","url":"https://stock-news.laohu8.com/highlight/detail?id=2623349259","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623349259?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:26","pubTimestamp":1774880766,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Kezar Life Sciences ( ($KZR) ). On March 30, 2026, Kezar Life Sciences agreed to be acquired by Aurinia Pharmac...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kezar-life-sciences-to-be-acquired-by-aurinia-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kezar-life-sciences-to-be-acquired-by-aurinia-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317885","title":"Aurinia to buy Kezar Life Sciences for USD 6.96 per share plus CVR","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317885","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317885?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:03","pubTimestamp":1774872182,"startTime":"0","endTime":"0","summary":"Aurinia agreed to acquire Kezar Life Sciences for USD 6.96 per share in cash.Kezar shareholders will also receive a non-transferable CVR tied to potential proceeds from zetomipzomib development or disposition, select collaboration and asset-sale proceeds, and excess closing net cash above USD 50 million.Aurinia plans to launch tender offer by April 13, 2026, for all outstanding Kezar shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on March 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL3PZ9wx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZR","AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623736312","title":"Aurinia Pharmaceuticals Inc - CVR Includes Payments From Zetomipzomib, Everest, Enodia, and Net Cash Over $50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623736312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623736312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872006,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA61LWRC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","KZR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312135","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:55 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312135","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312135?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:55","pubTimestamp":1774871700,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:55 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nAQN2LSEZE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KZR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622083438","title":"Kezar Life Sciences FY2025 operating loss narrows 34.8% to $(59) million; net loss narrows 33.1% to $(56) million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622083438","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622083438?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:16","pubTimestamp":1774642604,"startTime":"0","endTime":"0","summary":"Kezar published its annual report on Form 10-K, reporting a net loss of USD 56 million.Research and development expense fell 48.55% to USD 33.8 million, primarily due to lower clinical expenses after terminating the PALIZADE trial and completing the PORTOLA trial.General and administrative expense declined 20.94% to USD 18.5 million, driven mainly by lower stock-based compensation and personnel costs following restructuring.Restructuring and impairment charges rose more than tripled to USD 6.8 million, reflecting one-time severance costs and higher impairment on equipment no longer used after restructuring.Cash and cash equivalents were USD 71.9 million, and management said this is expected to fund projected operating requirements for at least the next 12 months.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8DXwND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KZR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kezarlifesciences.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.1164},{"period":"6month","weight":0.1834},{"period":"1year","weight":0.8089},{"period":"ytd","weight":0.159}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0691},{"period":"6month","weight":0.1244},{"period":"1year","weight":0.2335},{"period":"ytd","weight":0.076}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.084723},{"month":2,"riseRate":0.75,"avgChangeRate":0.08063},{"month":3,"riseRate":0.375,"avgChangeRate":-0.075957},{"month":4,"riseRate":0.25,"avgChangeRate":-0.073971},{"month":5,"riseRate":0.25,"avgChangeRate":-0.14246},{"month":6,"riseRate":0.428571,"avgChangeRate":0.046939},{"month":7,"riseRate":0.25,"avgChangeRate":-0.059399},{"month":8,"riseRate":0.5,"avgChangeRate":-0.012192},{"month":9,"riseRate":0.375,"avgChangeRate":0.031351},{"month":10,"riseRate":0.375,"avgChangeRate":0.02054},{"month":11,"riseRate":0.75,"avgChangeRate":0.152848},{"month":12,"riseRate":0.5,"avgChangeRate":0.034727}],"exchange":"NASDAQ","name":"Kezar Life Sciences Inc.","nameEN":"Kezar Life Sciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kezar Life Sciences Inc.(KZR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kezar Life Sciences Inc.(KZR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kezar Life Sciences Inc.,KZR,Kezar Life Sciences Inc.股票,Kezar Life Sciences Inc.股票老虎,Kezar Life Sciences Inc.股票老虎国际,Kezar Life Sciences Inc.行情,Kezar Life Sciences Inc.股票行情,Kezar Life Sciences Inc.股价,Kezar Life Sciences Inc.股市,Kezar Life Sciences Inc.股票价格,Kezar Life Sciences Inc.股票交易,Kezar Life Sciences Inc.股票购买,Kezar Life Sciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kezar Life Sciences Inc.(KZR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kezar Life Sciences Inc.(KZR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction